Hemophagocytic lymphohistiocytosis (HLH) is characterized by immune dysregulation due to inadequate restraint of overactivated immune cells and is associated with a variable clinical spectrum having overlap with more common pathophysiologies. HLH is difficult to diagnose and can be part of inflammatory syndromes. Here, we identify a novel hematological/autoinflammatory condition (NOCARH syndrome) in four unrelated patients with superimposable features, including neonatal-onset cytopenia with dyshematopoiesis, autoinflammation, rash, and HLH. Patients shared the same de novo CDC42 mutation (Chr1:22417990C>T, p.R186C) and altered hematopoietic compartment, immune dysregulation, and inflammation. CDC42 mutations had been associated with syndromic neurodevelopmental disorders. In vitro and in vivo assays documented unique effects of p.R186C on CDC42 localization and function, correlating with the distinctiveness of the trait. Emapalumab was critical to the survival of one patient, who underwent successful bone marrow transplantation. Early recognition of the disorder and establishment of treatment followed by bone marrow transplant are important to survival.
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function / Lam, M. T.; Coppola, S.; Krumbach, O. H. F.; Prencipe, G.; Insalaco, A.; Cifaldi, C.; Brigida, I.; Zara, E.; Scala, S.; Di Cesare, S.; Martinelli, S.; Di Rocco, M.; Pascarella, A.; Niceta, M.; Pantaleoni, F.; Ciolfi, A.; Netter, P.; Carisey, A. F.; Diehl, M.; Akbarzadeh, M.; Conti, F.; Merli, P.; Pastore, A.; Levi Mortera, S.; Camerini, S.; Farina, L.; Buchholzer, M.; Pannone, L.; Cao, T. N.; Coban-Akdemir, Z. H.; Jhangiani, S. N.; Muzny, D. M.; Gibbs, R. A.; Basso-Ricci, L.; Chiriaco, M.; Dvorsky, R.; Putignani, L.; Carsetti, R.; Janning, P.; Stray-Pedersen, A.; Erichsen, H. C.; Horne, A.; Bryceson, Y. T.; Torralba-Raga, L.; Ramme, K.; Rosti, V.; Bracaglia, C.; Messia, V.; Palma, P.; Finocchi, A.; Locatelli, F.; Chinn, I. K.; Lupski, J. R.; Mace, E. M.; Cancrini, C.; Aiuti, A.; Ahmadian, M. R.; Orange, J. S.; De Benedetti, F.; Tartaglia, M.. - In: THE JOURNAL OF EXPERIMENTAL MEDICINE. - ISSN 1540-9538. - 216:12(2019), pp. 2778-2799. [10.1084/jem.20190147]
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function
Zara E.;Locatelli F.;
2019
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is characterized by immune dysregulation due to inadequate restraint of overactivated immune cells and is associated with a variable clinical spectrum having overlap with more common pathophysiologies. HLH is difficult to diagnose and can be part of inflammatory syndromes. Here, we identify a novel hematological/autoinflammatory condition (NOCARH syndrome) in four unrelated patients with superimposable features, including neonatal-onset cytopenia with dyshematopoiesis, autoinflammation, rash, and HLH. Patients shared the same de novo CDC42 mutation (Chr1:22417990C>T, p.R186C) and altered hematopoietic compartment, immune dysregulation, and inflammation. CDC42 mutations had been associated with syndromic neurodevelopmental disorders. In vitro and in vivo assays documented unique effects of p.R186C on CDC42 localization and function, correlating with the distinctiveness of the trait. Emapalumab was critical to the survival of one patient, who underwent successful bone marrow transplantation. Early recognition of the disorder and establishment of treatment followed by bone marrow transplant are important to survival.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lam_A-novel-disorder_2019.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
4.22 MB
Formato
Adobe PDF
|
4.22 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
